Publications (1)5.4 Total impact
-
Article: 1. A non-fucosylated variant of the anti-HIV-1 MAb b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but not improved protection against mucosal SHIV challenge in macaques.
Journal of Virology 03/2012; · 5.40 Impact Factor